Hakkımda
Okullar / Eğitimler
- Eskişehir Osmangazi Üniversitesi Tıp Fakültesi
- Dokuz Eylül Üniversitesi Tıp Fakültesi İç Hastalıkları Anabilim Dalı İhtisas
- Marmara Üniversitesi Tıp Fakültesi İç Hastalıkları Anabilimdalı /Tıbbi Onkoloji Bd İhtisas
Yayınlar
- Fetuin-A İs Related To Syndesmophytes İn Patients With Ankylosing Spondylitis: A Case Control Study.2014. Clinics. Başoğlu Tüylü Tuğba, Sari İsmail, Solmaz Akgöl Dilek, Kozacı Didem Leyla, Akar Servet, Günay Necati, Önen Fatoş, Akkoç Nurullah (Uzmanlık Tez)
- Prognostic Value Of Tissue-Resident Memory T Cells And Tumor Microenvironmental Features İn Resected Pancreatic Adenocarcinoma.2022. Balkan Medical Journal. Başoğlu Tüylü Tuğba, Akar Kadriye Ebru, Bağcı Çulçi Pelin, Akgül Babacan Nalan, Öztürk Mehmet Akif, Öztürk Fatih Emin, Demircan Nazım Can, Arıkan Rukiye, Akın Telli Tuğba, Ercelep Özlem, Dane Faysal, Yumuk Perran Fulden(Yandal Uzmanlık Tez)
- Basoglu, Tugba, et al. "Triple-Negative Apocrine Carcinoma: Largest Cohort Highlights Unique Biology and Survival Advantage." Journal of Clinical Medicine 14.19 (2025): 7103.
- Demircan, N. C., Tekin, M. F., Akın Telli, T., Arıkan, R., Başoğlu, T., Çelebi, A., ... & Yumuk, P. F. (2025). Prognostic implications of cancer-associated fibroblasts and desmoplastic reaction in stage III colon cancer risk groups. Future Oncology, 1-10.
- Yıldırım, S., Alan, Ö., Türkoğlu, E., Busery, N. S., Doğan, A., Akdağ, G.,Basoglu,T. ... & Turan, N. (2025). Impact of Blood Type on Treatment Response and Survival in HER2-Negative Metastatic Gastric Cancer. Cerrahpaşa Medical Journal, 49(1), 1-6.
- Altıntaş, Y. E., Kınıkoğlu, O., Işık, D., Özkerim, U., Öksüz, S., Tünbekici, S.,Basoglu,T. ... & Turan, N. (2025). Association Between Prognostic Nutritional Index and Clinical Outcomes in Advanced Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors. Cerrahpaşa Medical Journal, 49(1), 1-7.
- Sever, Özlem Nuray, Tuğba Başoğlu, and Sedat Yıldırım. "Relationship of Tumor Localization and Lipid Parameters with Survival in Patients with Colorectal Cancer." Journal of Clinical Medicine 14.4 (2025): 1302.
- Surmeli, H., Turkoglu, E., Isik, D., Kinikoglu, O., Altintas, Y. E., Ozkerim, U., Basoglu, T.... & Turan, N. (2025, July). Effect of Family and Personal Medical History on Treatment Outcomes of Tyrosine Kinase Inhibitors (TKIs) in Non-Small Cell Lung Cancer (NSCLC). In Healthcare (Vol. 13, No. 15, p. 1810). MDPI.
- SEVER, Ö. N., BAŞOĞLU, T., KÖKTEN, Ş., & ODABAŞ, H. (2025). Long-term Follow-up Results of Our Patients Diagnosed with Ductal Carcinoma In Situ: Usefulness of the Van Nuys Prognostic Index. Journal of Oncological Sciences.
- Surmeli, H., Isik, D., Kinikoglu, O., Altintas, Y. E., Ozkerim, U., Oksuz, S.,Basoglu,T. ... & Turan, N. (2025). Impact of Age and Menopausal Status on T-DM1 (Ado-Trastuzumab Emtansine) Treatment Outcomes in HER2-Positive Breast Cancer. Pharmaceuticals, 18(6), 931.
- Turkoglu, E., Topal, G. A., Yıldırım, S., Kınıkoglu, O., Sarıyar Busery, N., Kaya, T.Basoglu, T. ... & Turan, N. (2025). The Association of Khorana Risk Score with Venous Thromboembolism and Overall Survival in Patients with Metastatic Gastric Cancer. Medicina, 61(6), 1075.
- Yıldırım, S., Başoğlu, T., Doğan, A., Akdağ, G., Kınıkoğlu, O., Topal, A., ... & Turan, N. (2025). The impact of carboplatin on pathologic complete response and survival based on HER2 low and HER2 zero status in triple negative breast cancer patients receiving neoadjuvant chemotherapy: a multicenter real-world analysis. BMC cancer, 25(1), 833.
- Oksuz, S., Kinikoglu, O., Ozkerim, U., Altintas, Y. E., Isik, D., Surmeli, H.,Basoglu, T. ... & Turan, N. (2025). Impact of HER2 Status Assessed by Immunohistochemistry on Treatment Response in Patients with Metastatic Breast Cancer Receiving Trastuzumab Emtansine. Medicina, 61(5), 819.
- Kınıkoğlu, O., Altıntaş, Y. E., Yıldız, A., Akdağ, G., Bal, H., Yaşar, Z. Y.,Basoglu,T. ... & Turan, N. (2025). Tumor-infiltrating lymphocytes as predictive biomarkers in neoadjuvant treatment of HER2-positive breast cancer. The Oncologist, 30(4), oyaf054.
- Altıntaş, Y. E., Kınıkoğlu, O., Işık, D., Özkerim, U., Öksüz, S., Başoğlu, T., ... & Turan, N. (2025). Pazopanib or Sunitinib as First-Line Treatment in metastatic Renal Cell Cancers: A Retrospective Comparative Analysis of Survival and Toxicity Outcomes. Eurasian Journal of Medical Investigation, 9(2).
- Altıntaş, Y. E., Kınıkoğlu, O., Işık, D., Güneş, T. K., Özkerim, U., Basoglu, T., ... & Turan, N. (2025). Very Favorable vs. Favorable Risk Groups in Metastatic Renal Cell Carcinoma: A Step Toward Personalized Treatment. Cancers, 17(7), 1076.
- A.,Basoglu,T. ... & Turan, N. (2025). Impact of Metastasectomy on Survival Outcomes in Colorectal Cancer: A Single Center Retrospective Study. Acta Haematologica Oncologica Turcica.
- Majidova, N., Arak, H., Ozalp, F. R., Bas, O., Koker, G. O., Ozmarasalı, E. B., Basoglu,T.... & Kostek, O. (2025). Prognostic factors and outcomes of adjuvant and first-line metastatic treatments in melanoma a Turkish oncology group study. Scientific reports, 15(1), 3200.
- Altıntaş, Y. E., Kınıkoğlu, O., Yıldız, A., Işık, D., Özkerim, U., Öksüz, S.,Basoglu,T. ... & Odabaş, H. (2024). Trastuzumab rechallenge in HER2-positive metastatic breast cancer: a promising strategy for enhanced progression-free survival post ado-trastuzumab emtansine progression. Medicina, 60(12), 2069.
- Real Life Experience Of Patients With Locally Advanced Gastric And Gastroesophageal Junction Adenocarcinoma Treated With Neoadjuvant Chemotherapy: A Turkish Oncology Group Study.2022
